Entering text into the input field will update the search result below

Johnson & Johnson backs away from Actelion

Dec. 13, 2016 6:50 PM ETJohnson & Johnson (JNJ) StockBy: Douglas W. House, SA News Editor25 Comments
  • Johnson & Johnson (NYSE:JNJ) has reportedly ended its negotiations with Actelion Pharmaceuticals (OTCPK:ALIOF) about a possible merger. J&J had made a $20B ($250/share) for the Basel, Switzerland-based biopharma firm, up from its original offer of $17B after Actelion resisted.
  • Sanofi (SNY) is reportedly mulling a bid as well.
  • Update: In a statement, J&J says its was unable to reach an agreement that it believed would "create adequate value" for its shareholders.

Recommended For You

About JNJ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
JNJ--
Johnson & Johnson